Please wait while the formulary information is being retrieved.
VISIPAQUE (IODIXANOL)
- Angiocardiography
- Cerebral arteriography
- Peripheral arteriography
- Peripheral venography
- Urography
270 mg iodine/mL intravenous solution
- Dosage information is not available
320 mg iodine/mL intravenous solution
- Dosage information is not available
- Actoplus Met
- Actoplus Met Xr
- alogliptin-metformin
- Fortamet
- glipizide-metformin
- Glucophage
- Glucophage Xr
- Glucovance
- Glumetza
- glyburide-metformin
- Janumet
- Janumet Xr
- Jentadueto
- Kazano
- Kombiglyze Xr
- linagliptin-metformin
- metformin
- pioglitazone-metformin
- Prandimet
- repaglinide-metformin
- Riomet
- saxagliptin-metformin
- sitagliptin-metformin
Contraindicated
- Methotrexate (anti-rheumatic)
- methotrexate sodium
- methotrexate sodium (PF)
- Rheumatrex
- Trexall
Severe
Moderate
- None
- None
Contraindicated
- Anuria
- Dehydration
- Disease of liver
- Hyperthyroidism
- Kidney disease with reduction in GFR
- Pheochromocytoma
- Seizure disorder
- Sickle cell disease
- Thyrotoxicosis
Severe
Moderate
- Asthma
- Hypertension
- Hypothyroidism
VISIPAQUE (IODIXANOL)
- Angiocardiography
- Cerebral arteriography
- Peripheral arteriography
- Peripheral venography
- Urography
- None
- None
More Frequent
Severe
Less Severe
- Angina
- Chest pain
- Dysgeusia
- Erythema
- Headache disorder
- Nausea
- Pruritus of skin
- Scotomata
- Vertigo
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute generalized exanthematous pustulosis
- Acute myocardial infarction
- Acute renal failure
- Anaphylaxis
- Cardiac arrhythmia
- Cerebrovascular accident
- DRESS syndrome
- Dyskinesia
- Dyspnea
- Hemorrhage
- Hypoglycemic disorder
- Hypotension
- Hypothyroidism
- Peripheral ischemia
- Polymyalgia rheumatica
- Pulmonary edema
- Respiratory depression
- Seizure disorder
- Shock
- Stevens-johnson syndrome
- Syncope
- Thromboembolic disorder
- Toxic epidermal necrolysis
Less Severe
- Acute confusion
- Agitation
- Back pain
- Bronchitis
- Diarrhea
- Dizziness
- Dyspepsia
- Edema
- Fatigue
- Flushing
- Hematoma
- Hematuria
- Hyperhidrosis
- Injection site sequelae
- Insomnia
- Malaise
- Memory impairment
- Paresthesia
- Rhinitis
- Skin rash
- Stupor
- Symptoms of anxiety
- Tinnitus
- Urticaria
- Visual changes
- Vomiting
Contraindicated
None
Severe Precaution
Iodixanol
Evaluate thyroid function within 3 weeks of exposure. Caution with prolonged fasting and laxative administration. Increased adverse events in patient with asthma, hypersensitive, cyanotic and acyanotic heart disease, congestive heart failure, serum creatinine greater than 1.5 mg/dL. Rare risk of apnea, disseminated intravascular coagulation, AV block, bundle branch block, cardiac or renal failure.
Contraindicated with prolonged fasting and laxative administration. Increased adverse events in patient with asthma, hypersensitive, cyanotic and acyanotic heart disease, congestive heart failure, serum creatinine greater than 1.5 mg/dL. Rare risk of hypothyroidism, apnea, disseminated intravascular coagulation, AV block, bundle branch block, cardiac or renal failure.
- 1 Day – 3 Years
- Evaluate thyroid function within 3 weeks of exposure. Caution with prolonged fasting and laxative administration. Increased adverse events in patient with asthma, hypersensitive, cyanotic and acyanotic heart disease, congestive heart failure, serum creatinine greater than 1.5 mg/dL. Rare risk of apnea, disseminated intravascular coagulation, AV block, bundle branch block, cardiac or renal failure.
- Contraindicated with prolonged fasting and laxative administration. Increased adverse events in patient with asthma, hypersensitive, cyanotic and acyanotic heart disease, congestive heart failure, serum creatinine greater than 1.5 mg/dL. Rare risk of hypothyroidism, apnea, disseminated intravascular coagulation, AV block, bundle branch block, cardiac or renal failure.
- 3 Years – 18 Years
- Evaluate thyroid function within 3 weeks of exposure. Caution with prolonged fasting and laxative administration. Increased adverse events in patient with asthma, hypersensitive, cyanotic and acyanotic heart disease, congestive heart failure, serum creatinine greater than 1.5 mg/dL. Rare risk of apnea, disseminated intravascular coagulation, AV block, bundle branch block, cardiac or renal failure.
- Contraindicated with prolonged fasting and laxative administration. Increased adverse events in patient with asthma, hypersensitive, cyanotic and acyanotic heart disease, congestive heart failure, serum creatinine greater than 1.5 mg/dL. Rare risk of hypothyroidism, apnea, disseminated intravascular coagulation, AV block, bundle branch block, cardiac or renal failure.
Management or Monitoring Precaution
None
Iodixanol
- Severity Level:
B
- Additional Notes: Consider maternal diagnostic benefit versus potential fetal adverse effects
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Iodixanol
Limited data suggest minimal amounts excreted; poor oral absorption
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Limited data suggest minimal amounts excreted; poor oral absorption |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Iodixanol
General-More sensitive to toxic effects. Requires adequate hydration before and after treatment.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | Y | N | N | Y |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
Formulary Reference Tool